Biomea Fusion (NASDAQ:BMEA) shares closed up on Friday as the company is presenting positive data from its Phase II COVALENT-111 study on icovamenib for type 2 diabetes.
The Phase II COVALENT-111 study results highlighted that icovamenib maintained a favorable safety profile throughout the 52-week observation period, with no serious treatment-related adverse events.
Additionally, the study showed statistically significant reductions in HbA1c levels among certain patient subgroups, suggesting icovamenib’s potential to transform diabetes treatment.
“We are encouraged by the durability of icovamenib’s effect observed nine months post-dosing at Week 52,” said Mick Hitchcock, Ph.D., Interim CEO and Board Member of Biomea Fusion. “We believe that we now have in hand initial evidence of durable efficacy, additional favorable safety data, a clear understanding of an effective dose, and most importantly, the target patient populations.”
The presentation at the 19th International Conference on Advanced Technologies & Treatments for Diabetes included data indicating that severe insulin-deficient patients experienced an HbA1c reduction of 1.2% at Week 52, with the most effective dosing regimen achieving a mean reduction of 1.5%.
This positive data is expected to bolster investor confidence as the company prepares for upcoming Phase II studies …
This post was originally published here
